Idarucizumab: The Antidote for Reversal of Dabigatran

Circulation. 2015 Dec 22;132(25):2412-22. doi: 10.1161/CIRCULATIONAHA.115.019628.

¹ From Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Department of Radiology, King's College Hospital, London, UK (D.J.Q.); and CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (J.v.R.).
² From Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Department of Radiology, King's College Hospital, London, UK (D.J.Q.); and CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (J.v.R.). dan.quinlan@nhs.net.

No abstract available

Keywords: anticoagulant; dabigatran; hemorrhage; idarucizumab.

Publication types